Retatrutide's Phase 2 trial data (Jastreboff et al., NEJM 2023) identified a side-effect profile broadly consistent with other incretin-based therapies: Gastrointestinal : Nausea, vomiting, diarrhoea, and constipation were the most commonly reported adverse effects, particularly during dose escalation
10.4103/jpn.JPN_130_19 4 BaoZ
How you draw and inject the solution matters just as much for consistent results
But the range for what's "normal" is debatable, so it's recommended to use at least two testing methods
Be sure to keep in mind that this procedure is supplemental to healthy weight loss habits
AOD-9604 is sold by Omnix Peptides strictly for laboratory, research, or analytical purposes